You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. A novel, hand-held, exhaled breath condensate sampler for the clinical research market; applications for asthma, pulmonary injury and inflammation.

    SBC: SENSIT VENTURES, INC.            Topic: NIEHS

    ABSTRACTExhaled breath is one of the most non-invasive human effluents that can be captured and analyzed, and yet it has minimal presence as a common clinical endpoint measurement in any branch of modern medicine. There has been a persistent technology gap for both breath sampling and breath analysis, despite the many vulnerable patient populations and age groups that could be aided by its use. Ex ...

    STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
  2. HBI-002 to Treat Diabetic Retinopathy

    SBC: Hillhurst Biopharmaceuticals, Inc.            Topic: NEI

    PROJECT SUMMARY Diabetic retinopathy (DR) is a neurovascular complication of diabetes mellitus and the leading cause of blindness in working age adults and elderly, affecting approximately 4.2 million diabetes patients in the US, of which 655,000 have vision-threatening DR. There is an urgent need for the development of additional approaches to prevent and treat diabetic retinopathy, as the curren ...

    STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
  3. Fingerprinting Cancer via Multiparameter Extracellular Vesicle Analysis

    SBC: ELECTRONIC BIOSCIENCES, INC.            Topic: 102

    Project Summary Electronic BioSciences (EBS) proposes, in collaboration with Distinguished Professor Henry White at the University of Utah, to develop a nanopore-based extracellular vesicle (EV) characterization system capable of high-resolution, single-vesicle, solution-based characterization, sorting, and isolation. EVs are nanometer-scale, cell-derived vesicles that are produced by nearly all m ...

    STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
  4. The Nanopore-based Ion Selective Electrode Vial

    SBC: ELECTRONIC BIOSCIENCES, INC.            Topic: 400

    Project Summary An electrolyte panel is a blood test that measures the levels of electrolytes and carbon dioxide in your blood. Electrolytes are chemicals found naturally in the body, such as potassium, calcium, sodium, and are needed to keep the bodyandapos;s balance of fluids at the proper level and to maintain normal functions, such as heart rhythm, muscle contraction, and brain function. CO2 i ...

    STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
  5. Mindfulness Based Stress Reduction Application for African American Caregivers

    SBC: COG ANALYTICS, LLC            Topic: NIA

    AbstractThere are approximately 43.5 million informal (unpaid) caregivers in the U.S., of which 5.6 million are African American. Informal caregivers often provide a variety of types of support including emotional, physical, and financial, to people with chronic conditions.1 Providing care can be very stressful and emotionally and physically exhausting for informal caregivers.2 African American ca ...

    STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
  6. Lipid Receptor GPR31 as a Target for Anti-Thrombotic and Stroke Therapy

    SBC: OASIS PHARMACEUTICALS, LLC            Topic: NHLBI

    Despite prevalent use of anti-platelet and anti-lipid therapies, stroke remains the third major cause of death and is the leading cause of adult disability in the US with an estimated cost in the range of $34 billion annually. Approximately 20% of the annual 795,000 stroke patients die within one year and 15-30% are permanently disabled. Antiplatelet therapy is mainly used for primary prevention o ...

    STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
  7. An automated system to interpret echocardiography to predict adverse outcomes in patients with right ventricular dysfunction in daily hospital practice

    SBC: MPROBE, INC.            Topic: NHLBI

    Project Summary Right ventricle (RV) dysfunction is a common and complex form of pediatric heart disease. It is also a common contributor to morbidity and mortality for patients with congenital heart diseases (CHD). Due to the complex geometry of the RV and its relative adaptability to changing physiologic conditions, RV dysfunction is poorly understood and difficult to characterize precisely and ...

    STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
  8. AlgenML: Drug target discovery platform for transcriptional reprogramming of MYCN-driven neuroblastoma

    SBC: Algen Biotechnologies Inc            Topic: 400

    AlgenML: Drug target discovery platform for transcriptional reprogramming of MYCN-driven neuroblastoma PROJECT SUMMARY Drug discovery is a laborious, time-consuming, and expensive undertaking for biopharma. Oncology is especially difficult with new drugs in clinical trials having just 3.4% probability of success. This application addresses significant challenges of traditional drug target discover ...

    STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
  9. Cancer Immunotherapy Targeting Tn Antigen

    SBC: GlyTR Therapeutics, Inc.            Topic: 100

    AbstractCancer immunotherapeutic bi-specific proteins and engineered Chimeric Antigen Receptor T cells (CAR T) have shown remarkable clinical activity, with complete response rates as high as ~90% for B cell malignancies. However, applying these two therapeutic approaches to the vast majority of cancer types is restricted by multiple factors. First, there are only a small number of known cell-surf ...

    STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
  10. Development of Small Molecule Antagonists of PAR-2 for treatment of asthma

    SBC: PARMEDICS, INC.            Topic: NHLBI

    ABSTRACT: Current treatments for asthma largely are aimed at reducing exacerbations by directly treating airway inflammation. While successful in a subset of patients, asthma exacerbations remain a significant cause of morbidity and mortality and can result in airway injury, lung function decline and death. Exacerbations in more severe asthmatics are of particular concern, as health care costs and ...

    STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government